@timmychoo_'s week one tirzepatide claims, fact-checked
Quick answer
The creator describes classic early-phase tirzepatide side effects including severe nausea and GI distress following a first dose, resulting in significantly reduced caloric intake over three days. The 7-pound first-week loss almost certainly reflects fluid and glycogen depletion rather than meaningful fat reduction, which is consistent with how GLP-1 and GIP receptor agonists behave at initiation. Her provider's comment about peak results in months two and three likely reflects a standard dose titration schedule, where therapeutic doses are not reached until several weeks into treatment.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @timmychoo_ actually say?
@timmychoo_ reported losing 7 pounds in her first week on a GLP-1 medication, which she identifies as tirzepatide. She attributes most of that loss to barely eating for three days after her first injection, describing severe nausea and gastrointestinal distress. She also claims her provider told her "most people see the highest amount of weight loss in month two and month three" on the medication. She recommends water, avoiding alcohol and spicy foods, staying active, and pairs all of this with a referral link and affiliate discount code for what appears to be a telehealth platform called Body Envy.
The video reads as a personal experience post, but the affiliate link in her bio and the $100 discount code make it a commercial promotion, whether she labels it that way or not. That context matters for how you interpret everything she says.
Does the science back this up?
Some of it, yes. The nausea and appetite suppression she describes are well-documented, expected effects of tirzepatide, not a bug. The claim about greater weight loss in months two and three is partially supported by trial data, though not quite how she frames it.
Tirzepatide works as a dual GIP and GLP-1 receptor agonist. In the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), participants on the 15mg dose lost a mean of 20.9% of body weight over 72 weeks. Early weight loss in week one is largely water weight and glycogen depletion, not fat loss. The steepest fat loss in that trial occurred over the first several months as doses were titrated upward. So her provider's comment about months two and three has some basis, but it reflects dose escalation schedules more than some biological switch flipping.
Her advice to avoid alcohol and spicy foods during GI-heavy early weeks is reasonable and consistent with standard clinical guidance for GLP-1 users managing nausea.
What did they get wrong (or right)?
She got the lifestyle framing mostly right. "A GLP-1 is not magic so you have to work with it not against it" is genuinely good advice and something a lot of influencer posts skip entirely.
What she got wrong, or at least incomplete: 7 pounds in a week is not a meaningful weight loss benchmark. Rapid early loss on any GLP-1 is primarily fluid, not fat. Presenting it as a seven-pound result without that context sets expectations that are likely to discourage people when week two or three looks nothing like week one. Pihl et al. (2023, Obesity Reviews) noted that unrealistic early expectations are a leading cause of early discontinuation in GLP-1 therapy, which is a real clinical problem.
She also misspells the drug name as "Tirezepatide" in the caption. Minor, but for a post that's functionally an advertisement for a telehealth service, accuracy on the medication name seems like the floor.
The affiliate relationship is not disclosed with any FTC-required clarity. A link in bio with a discount code is a commercial arrangement and should be labeled as such.
What should you actually know?
First week results on tirzepatide are not predictive of long-term outcomes. Do not use them as a baseline.
The gastrointestinal side effects she describes, nausea, diarrhea, appetite suppression severe enough to not eat for three days, are common but not universal and not something to push through without talking to a provider. The SURMOUNT-1 trial reported that roughly 4-6% of participants discontinued tirzepatide due to GI adverse events (Jastreboff et al., 2022). Not eating for three days is not a feature. It is a side effect that warrants a conversation with your prescribing clinician.
If you are considering a GLP-1 through a telehealth platform, ask specifically whether you are being prescribed a brand-name FDA-approved drug or a compounded version. These are not the same product. Compounded tirzepatide has different regulatory oversight, and the FDA has issued warnings about compounded GLP-1 products. Any platform that obscures this distinction is not giving you full information.
Her general lifestyle advice, staying active, drinking water, watching what you eat, is not wrong. But it also is not sufficient guidance for starting a prescription medication.
Bottom line on @timmychoo_'s video
This is a first-week personal experience post with an undisclosed affiliate arrangement. The creator gives some genuinely reasonable lifestyle advice and is honest that her dramatic first-week loss was probably driven by not eating. That self-awareness is refreshing. But 7 pounds in a week is a misleading headline for what is mostly fluid loss during a period of medication-induced nausea. The science on tirzepatide is strong, but this video is not a reliable guide to what your experience will look like, and it is not a substitute for a clinical consultation.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @timmychoo_'s week one tirzepatide claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Tirzepatide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Claim verdict
The useful answer behind this video
Claim being checked
The creator describes classic early-phase tirzepatide side effects including severe nausea and GI distress following a first dose, resulting in significantly reduced caloric intake over three days.
FormBlends verdict
The creator describes classic early-phase tirzepatide side effects including severe nausea and GI distress following a first dose, resulting in significantly reduced caloric intake over three days. The 7-pound first-week loss almost certainly reflects fluid and glycogen depletion rather than meaningful fat reduction, which is consistent with how GLP-1 and GIP receptor agonists behave at initiation. Her provider's comment about peak results in months two and three likely reflects a standard dose titration schedule, where therapeutic doses are not reached until several weeks into treatment.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator describes classic early-phase tirzepatide side effects including severe nausea and GI distress following a first dose, resulting in significantly reduced caloric intake over three days. The 7-pound first-week loss almost certainly reflects fluid and glycogen depletion rather than meaningful fat reduction, which is consistent with how GLP-1 and GIP receptor agonists behave at initiation. Her provider's comment about peak results in months two and three likely reflects a standard dose titration schedule, where therapeutic doses are not reached until several weeks into treatment.
- In SURMOUNT-1 (Jastreboff et al., 2022, NEJM), mean weight loss with 15mg tirzepatide was 20.9% over 72 weeks. Week-one numbers are not predictive of that trajectory.
- First-week weight loss on GLP-1 medications is primarily water and glycogen, not fat. It is not a meaningful clinical benchmark.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- In SURMOUNT-1 (Jastreboff et al., 2022, NEJM), mean weight loss with 15mg tirzepatide was 20.9% over 72 weeks. Week-one numbers are not predictive of that trajectory.
- First-week weight loss on GLP-1 medications is primarily water and glycogen, not fat. It is not a meaningful clinical benchmark.
- Roughly 4-6% of SURMOUNT-1 participants discontinued tirzepatide due to GI adverse events. Not eating for three days is a side effect to discuss with your provider, not a weight loss strategy.
- Compounded tirzepatide and brand-name tirzepatide (Zepbound, Mounjaro) are not equivalent products. The FDA has issued warnings about compounded GLP-1 formulations and they carry different regulatory status.
- Dose titration schedules, not a biological shift, explain why weight loss tends to accelerate in months two and three. Most protocols start at 2.5mg and escalate over 4-20 weeks to therapeutic doses.
- Lifestyle factors including physical activity and dietary quality improve outcomes on tirzepatide. The creator's advice here is consistent with clinical guidance, even if the rest of the video is not a substitute for it.
- The affiliate link and $100 discount code in this video represent a commercial relationship that is not clearly disclosed, which affects how the content should be evaluated.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
TimmyChoo | Detroit Influencer · TikTok creator
127.2K views on this video
Yall have been asking and here’s the results for week one on Tirezepatide. I’m down 7 pounds but I didn’t really eat the first three days. If you need more info you can click the 🔗 in my bí0 and get
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by TimmyChoo | Detroit Influencer, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.